Do I Qualify for Weight Loss Medication?

With GLP-1 medications generating so much attention, one of the most common questions people ask is simply: "Would I qualify?" The answer depends on a few specific criteria — plus a medical evaluation to rule out conditions that make these drugs unsafe.

Here's how physicians think about it.

The BMI Criteria

The most common starting point is BMI (Body Mass Index), a rough measure of weight relative to height. The standard criteria for weight loss medications like Wegovy (semaglutide) or Zepbound (tirzepatide) are:

• BMI of 30 or higher — regardless of other health conditions, or
• BMI of 27 or higher — if you also have at least one weight-related health condition

These cutoffs match the BMI thresholds used in the [STEP 1 trial of semaglutide](https://pubmed.ncbi.nlm.nih.gov/33567185/) and the [SURMOUNT-1 trial of tirzepatide](https://pubmed.ncbi.nlm.nih.gov/35658024/) — the studies that led to FDA approval for weight management.

Weight-related conditions that qualify include:

• Type 2 diabetes or prediabetes
• High blood pressure (hypertension)
• High cholesterol (dyslipidemia)
• Obstructive sleep apnea
• Cardiovascular disease

So if your BMI is 28 and you have high blood pressure, you would meet the criteria under current guidelines. If your BMI is 28 with no other conditions, you typically wouldn't.

BMI Has Limitations — And Good Physicians Know This

BMI is an imperfect tool. It doesn't account for muscle mass, body composition, bone density, or where fat is distributed in your body. Two people with the same BMI can have very different health profiles.

A physician who's paying attention will also consider your waist circumference, metabolic bloodwork, and your history of weight-related symptoms — not just the number on the BMI chart.

What Makes Someone NOT a Candidate

There are several contraindications that would make a physician pause or decline to prescribe GLP-1 medications:

Personal or family history of certain thyroid cancers

GLP-1 medications carry a boxed warning regarding a rare form of thyroid cancer called medullary thyroid carcinoma (MTC). People with a personal or family history of MTC, or a rare genetic condition called Multiple Endocrine Neoplasia type 2 (MEN2), should not use these medications.

Pancreatitis history

GLP-1 drugs have been associated with pancreatitis. People with a history of pancreatitis require careful evaluation before any GLP-1 therapy.

Pregnancy or plans to become pregnant

These medications are not recommended during pregnancy. Women who are pregnant or planning to conceive should not use GLP-1 medications.

Severe gastroparesis

Because GLP-1 drugs slow gastric emptying, they can worsen gastroparesis (delayed stomach emptying). This is a contraindication.

Severe kidney or liver disease

These conditions require individual assessment.

What a Medical Evaluation Includes

A responsible prescribing evaluation isn't just a brief questionnaire. Your physician will want to know:

• Your complete health history, including all current conditions
• All medications you're taking (including supplements)
• Prior weight loss attempts and results
• Family history relevant to thyroid or pancreatic conditions
• Current lab values — or will order them if you don't have recent bloodwork

At Coral Health, Dr. Kim reviews every intake personally before any recommendation is made.

What If You Don't Quite Meet the BMI Threshold?

If your BMI is just below 27 or 30, the situation isn't necessarily closed. Weight-related conditions, metabolic markers, cardiovascular risk factors, and quality-of-life considerations all inform the clinical picture. A conversation with a physician who takes the time to understand your full history is the right first step.

[Find out if you qualify](/start) — quick telehealth evaluation with a real physician.

---

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33567185/)
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35658024/)

---

Related Articles

• [How Much Does Semaglutide Cost Per Month?](/blog/semaglutide-cost-per-month-2026)
• [Can a Telehealth Doctor Prescribe Ozempic?](/blog/can-a-telehealth-doctor-prescribe-ozempic)
• [Online Doctor for Weight Loss Prescription in Florida](/blog/online-doctor-weight-loss-prescription-florida)